BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst with JPMorgan, and we're delighted to be continuing the 40th Annual Healthcare Conference today with BioCryst.
I'm joined by the company's CEO, Jon Stonehouse. He's going to give you a presentation, and then we're going to go into some Q&A after that. (Operator Instructions)
So with that out of the way, let me turn it over to Jon.
Thanks, Jess, and thanks for inviting us to this year's JPMorgan Healthcare Conference. Before I start, I'd like to remind you that I'll be making some forward-looking statements, and those statements have risks and the risk factors can be found on our website.
Not sure anyone's ever started a JPMorgan presentation with a 0 on the first slide, but a little more than a year ago, that's what we had from our rare disease oral drug portfolio. And then, well,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
